Table 2.

Recipients, donors, and CBT characteristics with available CBU samples, HLA-HR data, and according to CTLA4-CBU genotyping (n = 305)

RecipientsAA-CBU genotyping, n = 73AG-CBU genotyping, n = 153GG-CBU genotyping, n = 79
Male sex, n 32 93 51 
Age, median (range), y 13 (0.7-56) 13 (0.8-60) 11 (0.7-48) 
Weight, median (range), kg 39 (7-93) 50 (7-112) 36 (6-94) 
Children ≤18 y, n 45 91 55 
Positive CMV serology, n 43 91 46 
Major ABO incompatibility, n 13 49 29 
Diagnostic, n    
 ALL 36 82 42 
 AML 28 57 24 
 MDS 14 13 
HLA compatibility, n    
 8/8 
 7/8 17 14 
 6/8 18 40 18 
 5/8 21 45 32 
 4/8 13 34 12 
 3/8 
Disease status at time of CBT, n    
 Early 32 66 27 
 Intermediate 28 56 30 
 Advanced 13 31 22 
GVHD prophylaxis, n    
 CsA ± others 68 137 71 
 MTX ± others 
 Others 
Use of ATG and /or monoclonal antibody, n    
 Yes 
 No 62 139 68 
Infused TNC dose,
median (range), ×107/kg 
3.7 (1-17) 3.4 (1-19) 3.9 (1-20) 
Infused CD34+ cell dose, median (range), ×105/kg 1.8 (0.3-18) 1.7 (0.2-9) 1.6 (0.3-17) 
Follow-up (range), mo 59 (4-125) 60 (3-145) 40 (6-86) 
RecipientsAA-CBU genotyping, n = 73AG-CBU genotyping, n = 153GG-CBU genotyping, n = 79
Male sex, n 32 93 51 
Age, median (range), y 13 (0.7-56) 13 (0.8-60) 11 (0.7-48) 
Weight, median (range), kg 39 (7-93) 50 (7-112) 36 (6-94) 
Children ≤18 y, n 45 91 55 
Positive CMV serology, n 43 91 46 
Major ABO incompatibility, n 13 49 29 
Diagnostic, n    
 ALL 36 82 42 
 AML 28 57 24 
 MDS 14 13 
HLA compatibility, n    
 8/8 
 7/8 17 14 
 6/8 18 40 18 
 5/8 21 45 32 
 4/8 13 34 12 
 3/8 
Disease status at time of CBT, n    
 Early 32 66 27 
 Intermediate 28 56 30 
 Advanced 13 31 22 
GVHD prophylaxis, n    
 CsA ± others 68 137 71 
 MTX ± others 
 Others 
Use of ATG and /or monoclonal antibody, n    
 Yes 
 No 62 139 68 
Infused TNC dose,
median (range), ×107/kg 
3.7 (1-17) 3.4 (1-19) 3.9 (1-20) 
Infused CD34+ cell dose, median (range), ×105/kg 1.8 (0.3-18) 1.7 (0.2-9) 1.6 (0.3-17) 
Follow-up (range), mo 59 (4-125) 60 (3-145) 40 (6-86) 

This cohort is a subset of recipients with available CBU (n = 696).

HR-HLA, high-resolution HLA. Other abbreviations are explained in Table 1.

Close Modal

or Create an Account

Close Modal
Close Modal